Videos

Approaching a Case of Stage 3C Ovarian Cancer

April 30th 2018

A Case of Recurrent Ovarian Cancer

April 30th 2018

A Case of Recurrent Ovarian Cancer

Ovarian Cancer: Looking Toward Later-Line Therapy

April 27th 2018

Managing PARP Inhibitor Toxicities in Ovarian Cancer

April 27th 2018

Rucaparib in Recurrent Ovarian Cancer: ARIEL3 Trial

April 27th 2018

Optimizing Therapy in Recurrent Ovarian Cancer

April 27th 2018

Frontline Bevacizumab Strategies in Ovarian Cancer

April 27th 2018

Approaching a Case of Advanced Serous Ovarian Cancer

April 27th 2018

A Case of Advanced Serous Ovarian Cancer

April 27th 2018

A Case of Advanced Serous Ovarian Cancer

Recurrent Ovarian Cancer: Third-Line Therapy and Beyond

April 27th 2018

Defining Rucaparib's Value in Recurrent Ovarian Cancer

April 27th 2018

Recurrent Ovarian Cancer: Selecting Second-Line Therapy

April 27th 2018

Approaching Frontline Therapy Options for Ovarian Cancer

April 27th 2018

A Case of Platinum-Sensitive Epithelial Ovarian Cancer

April 27th 2018

A Case of Platinum-Sensitive Epithelial Ovarian Cancer

April 27th 2018

A Case of Platinum-Sensitive Epithelial Ovarian Cancer

CLL: Combination Therapies and Future Outlook

April 27th 2018

Therapeutic Approach for CLL Progression

April 27th 2018

CLL: Rationale for Ibrutinib and Chemotherapy

April 27th 2018

Treatment Options for CLL

April 27th 2018

Risk Stratifying a Case of CLL

April 27th 2018

Treating Chronic Lymphocytic Leukemia in Elderly Patients

April 27th 2018

Treating Chronic Lymphocytic Leukemia in Elderly Patients

Case 4: Maintenance Strategies in CLL

April 26th 2018

Case 4: iFCR in Untreated CLL

April 26th 2018

Case 4: iFCG in Untreated CLL

April 26th 2018

Case 4: A Young, Fit Patient With MRD-Positive CLL After Immunochemotherapy

April 26th 2018

Case 3: Therapeutic Approaches for Richter Transformation

April 26th 2018

Case 3: Progression on Ibrutinib Followed by Richter Transformation

April 26th 2018

Case 3: Response to Frontline Therapy and Toxicity Management

April 26th 2018

Case 3: Elderly Patient With CLL, Mutated TP53 and NOTCH, Unmutated IgHV

April 26th 2018

Case 2: Treatment Options: Venetoclax +/- Rituximab

April 26th 2018

Videos

Approaching a Case of Stage 3C Ovarian Cancer

A Case of Recurrent Ovarian Cancer

Ovarian Cancer: Looking Toward Later-Line Therapy

Managing PARP Inhibitor Toxicities in Ovarian Cancer

Rucaparib in Recurrent Ovarian Cancer: ARIEL3 Trial

Optimizing Therapy in Recurrent Ovarian Cancer

Frontline Bevacizumab Strategies in Ovarian Cancer

Approaching a Case of Advanced Serous Ovarian Cancer

A Case of Advanced Serous Ovarian Cancer

Recurrent Ovarian Cancer: Third-Line Therapy and Beyond

Defining Rucaparib's Value in Recurrent Ovarian Cancer

Recurrent Ovarian Cancer: Selecting Second-Line Therapy

Approaching Frontline Therapy Options for Ovarian Cancer

A Case of Platinum-Sensitive Epithelial Ovarian Cancer

A Case of Platinum-Sensitive Epithelial Ovarian Cancer

CLL: Combination Therapies and Future Outlook

Therapeutic Approach for CLL Progression

CLL: Rationale for Ibrutinib and Chemotherapy

Treatment Options for CLL

Risk Stratifying a Case of CLL

Treating Chronic Lymphocytic Leukemia in Elderly Patients

Case 4: Maintenance Strategies in CLL

Case 4: iFCR in Untreated CLL

Case 4: iFCG in Untreated CLL

Case 4: A Young, Fit Patient With MRD-Positive CLL After Immunochemotherapy

Case 3: Therapeutic Approaches for Richter Transformation

Case 3: Progression on Ibrutinib Followed by Richter Transformation

Case 3: Response to Frontline Therapy and Toxicity Management

Case 3: Elderly Patient With CLL, Mutated TP53 and NOTCH, Unmutated IgHV

Case 2: Treatment Options: Venetoclax +/- Rituximab

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Melanoma Survival Is Tied to Comorbidity Burden, Illuminating Care Opportunities

Beyond SC Daratumumab: Emerging Therapeutic Approaches for Smoldering Myeloma

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors

Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma

IGV-001 Offers Hope for Prolonged OS in Newly Diagnosed Glioblastoma